CRDF Cardiff Oncology, Inc.

NASDAQ
$0.73

Cardiff Oncology, Inc. (CRDF) is expected to report earnings on February 11, 2027, after the market close. The consensus earnings estimate is a loss of $0.15 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -3.2% since its last earnings release on November 12, 2026.

Cardiff Oncology, Inc. Beat Consensus Estimates
Thursday, November 12, 2026 · 7:00 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 11
Thursday · 4:10 PM ET
Earnings Whisper
-
vs ($0.15)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $0.73

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Cardiff Oncology, Inc.

Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.